Date Title
March 12, 2018
Realm Therapeutics - Second Price Monitoring Extn
RNS Number : 4711H Realm Therapeutics PLC 12 March 2018   Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.
March 12, 2018
Realm Therapeutics - Price Monitoring Extension
RNS Number : 4704H Realm Therapeutics PLC 12 March 2018   Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders
March 12, 2018
Realm Therapeutics - Clinical Update including PR013 Phase II results
RNS Number : 3372H Realm Therapeutics PLC 12 March 2018   THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014   Realm Therapeutics Provides Clinical Update, including Results from a Phase 2 Study of PR013 in Allergic Conjunctivitis   MALVERN, PA ,
March 8, 2018
Realm Therapeutics - Presenting at Cowen Healthcare Conference
RNS Number : 0452H Realm Therapeutics PLC 08 March 2018   Realm Therapeutics to Present at the Cowen and Company 38 th Annual Health Care Conference   MALVERN, PA , March 8 2018 - Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics
February 27, 2018
Realm Therapeutics - Patent portfolio strengthened with USPTO allowance
RNS Number : 9683F Realm Therapeutics PLC 27 February 2018   Realm Therapeutics Strengthens its Patent Portfolio with Two New USPTO Notice of Allowances   MALVERN, PA , February 27, 2018 - Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel
February 20, 2018
Realm Therapeutics - Presentation at RBC Healthcare Conference
RNS Number : 3995F Realm Therapeutics PLC 20 February 2018   Realm Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference   MALVERN, PA , February 20, 2018 - Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel
February 16, 2018
Realm Therapeutics - Block listing Interim Review
RNS Number : 3663E Realm Therapeutics PLC 16 February 2018   Realm Therapeutics plc Block Listing Interim Review   Pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies Realm Therapeutics plc makes the following update on its block listing:   Date:   16 February 2018   Name of
February 15, 2018
Realm Therapeutics - Clinical and Business Update
RNS Number : 9394E Realm Therapeutics PLC 15 February 2018   Realm Therapeutics Highlights Strong 2017 Performance and Outlines 2018 Milestones   Phase 2 Allergic Conjunctivitis Study Ahead of Schedule; Top-Line Results Anticipated by End of Q1   Phase 2 Atopic Dermatitis Study on Track with
January 2, 2018
Realm Therapeutics - Presents at 5th Annual Dermatology Summit
RNS Number : 5854A Realm Therapeutics PLC 02 January 2018   Realm Therapeutics to Present at the 5 th Annual Dermatology Summit   MALVERN, PA , January 2 2018 - Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory
December 15, 2017
Realm Therapeutics - Director/PDMR Shareholding
RNS Number : 4271Z Realm Therapeutics PLC 15 December 2017   Realm Therapeutics plc ("Realm Therapeutics", "Realm" or the "Company")   Grant of Options   15 December 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary
Displaying 21 - 30 of 136

Search Investor Relations